Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$101.10
▼ $3.85 (-3.7%)
Market data updated: 09/19 03:07 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$3.02B
Day Range
$99.70 - $105.00
52-Week Range
$32.21 - $170.87
Beta
—
Next Earnings
26.10.2026
Support
$58.14
Resistance
$105.18
WGS is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
-18.0% (1Y)
Strengths: 22/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 40.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $14.53 vs. price $101.10 (-85.6%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
66
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $102.65
Evidence: Euphoria score crossed 55 (now 61)
What happened after
Still awaiting outcome
1d ago · $102.65
Evidence: FOMO score jumped from 30 to 63 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
63
Value
38
Momentum
85
Risk
62
Sentiment
92
Fundamental
39
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **GeneDx Holdings Corp.** has highlighted its leadership in **genomic diagnostics**, particularly its role in advancing **rapid genome sequencing** for pediatric care. A key focus was a **transformative study** with Seattle Children’s demonstrating how hospital-wide adoption of its technology improves diagnostic accuracy, patient outcomes, and operational efficiency. Additionally, CEO **Katherine Stueland** was recognized as a **2026 Fierce 50 Honoree** for health equity contributions. The company was also briefly mentioned in broader genomics and stock momentum discussions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about GeneDx Holdings Corp.. News trend score: 92. Reason: 8 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
75
🎯 Conviction (vs. Emotion)
43
Investors appear highly excited (75), but evidence of strong fundamental conviction is comparatively weak (43).
Psychology
96
Fundamentals
39
Technical
85
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+78%
Market Narrative
97
Fundamental Reality
43
Narrative Gap
+54
🧠 StockIQ Psychologist
The market behavior suggests a strong euphoria around WGS, driven by robust price momentum, a large premium to its 200‑day average and DCF valuation, and flawless news sentiment. Overconfidence is also evident, as price gains far exceed modest EPS growth and the valuation gap is extreme. However, the modest FOMO score and low volume hint that buying enthusiasm may be limited. An open question is whether earnings can justify the lofty price levels. A negative earnings surprise could temper the current optimism.
Updated: 09/09/2026, 12:28 PM
What could change this?
👥 What the crowd believes
"Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity"
"hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children"
"broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis"
"GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations"
🧠 Market Brain events driving this
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 94/100
🔴 Weakest match
Samuel Armstrong Nelson — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between growth-focused and more conservative methodologies. Peter Lynch and Walter Bagehot’s near-perfect scores reflect their enthusiasm for high-growth potential and resilient liquidity, suggesting the company’s momentum hasn’t yet been fully priced in. Meanwhile, Fisher and Smith’s solid but lower scores highlight its strong fundamentals and long-term potential, though not at the extreme Lynch would target. On the other end, Graham’s strict criteria and Marks’ late-cycle warnings flag valuation and risk concerns, while Livermore and Veblen’s lukewarm signals question whether the growth translates into sustainable profitability. The efficient-market camp dismisses it as unexceptional, while Mackay’s skepticism hints at speculative bubbles—showing how a single stock can simultaneously appeal to bulls and alarm contrarians.
Peter Lynch
One Up on Wall Street (1989)
🟢 94
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 90
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 82
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 60
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 54
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 40
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 36
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 34
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 25
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 10
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 0
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
69.7%
Operating Margin
-3.1%
Net Margin
-4.9%
EBITDA Margin
-0.8%
ROE
-6.8%
ROA
-4.0%
ROIC
—
EPS
-$0.73
Cash
$105.00M
Total Debt
$52.72M
Current Ratio
2.46
Debt/Equity
0.17
How is Fair Value calculated? →
Current Price
$101.10
Estimated Fair Value (DCF)
$14.53
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-85.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $17.83M | $16.36M |
| 2 | 19.4% | $21.28M | $17.91M |
| 3 | 13.8% | $24.21M | $18.69M |
| 4 | 8.1% | $26.17M | $18.54M |
| 5 | 2.5% | $26.83M | $17.44M |
Base FCF (last actual year)
$14.26M
Terminal Value
$423.07M
Present Value of Terminal Value
$274.97M
Enterprise Value
$363.91M
Net Debt
$-52.28M
Equity Value
$416.19M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$10.76
Tangible Book Value per Share (Tangible NAV)
$4.41
Sentiment based on basic keywords (not AI) — 8 positive, 11 neutral, 1 negative out of the last 20 articles.
Yahoo · 9.9.2026
Business Wire · 9.9.2026
Benzinga · 9.9.2026
Zacks · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Benzinga · 26.8.2026
Yahoo · 24.8.2026
Zacks · 24.8.2026
Yahoo · 24.8.2026
Business Wire · 24.8.2026
Benzinga · 24.8.2026
Zacks · 19.8.2026
SeekingAlpha · 18.8.2026
Business Wire · 11.8.2026
Motley Fool · 11.8.2026
Simply Wall St. · 8.8.2026
Business Wire · 6.8.2026
SeekingAlpha · 6.8.2026
GeneDx Holdings Corp. (WGS) currently has a StockIQ AI score of 66/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
WGS currently scores 66/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, WGS's estimated fair value is $14.53, which is 85.6% below the current price of $101.10. This is one valuation model among several signals in the fair-value category, not a price target.
WGS's technical score is 85/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 40.0%; Earnings per share (EPS) growth: 62.4%; Free cash flow growth: 142.0%.
Based on the real signals StockIQ computed: Estimated fair value: $14.53 vs. price $101.10 (-85.6%); Operating margin: -3.1% (negative); Net margin: -4.9% (negative).
StockIQ has no recorded dividend payment history for WGS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Stueland Katherine | Open Market Sale | 9.9.2026 | 3,692 | -3,692 | $84.22 |
| Stueland Katherine | Exercise of Derivative Securities | 9.9.2026 | 6,547 | -6,547 | — |
| Feeley Kevin | Exercise of Derivative Securities | 9.9.2026 | 2,462 | +2,462 | — |
| Feeley Kevin | Exercise of Derivative Securities | 9.9.2026 | 2,462 | -2,462 | — |
| Stueland Katherine | Exercise of Derivative Securities | 9.9.2026 | 6,547 | +6,547 | — |
| Feeley Kevin | Open Market Sale | 9.9.2026 | 1,285 | -1,285 | $84.22 |
| Feeley Kevin | Open Market Sale | 1.9.2026 | 372 | -372 | $83.84 |
| Feeley Kevin | Exercise of Derivative Securities | 1.9.2026 | 717 | -717 | — |
| Feeley Kevin | Exercise of Derivative Securities | 1.9.2026 | 717 | +717 | — |
| GARDNER MARK A | Grant/Award from Employer | 29.6.2026 | 35,441 | +35,441 | — |
| GARDNER MARK A | Grant/Award from Employer | 29.6.2026 | 35,441 | +35,441 | — |
| PFENNIGER RICHARD C JR | Exercise of Derivative Securities | 18.6.2026 | 3,576 | +3,576 | — |
| Leproust Emily M. | Grant/Award from Employer | 18.6.2026 | 4,248 | +4,248 | — |
| Leproust Emily M. | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
| PFENNIGER RICHARD C JR | Grant/Award from Employer | 18.6.2026 | 4,248 | +4,248 | — |
| RUCH JOSHUA | Exercise of Derivative Securities | 18.6.2026 | 3,576 | +3,576 | — |
| Meister Keith A. | Grant/Award from Employer | 18.6.2026 | 4,248 | +4,248 | — |
| RUCH JOSHUA | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
| PFENNIGER RICHARD C JR | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
| Fuchs Thomas | Grant/Award from Employer | 18.6.2026 | 4,248 | +4,248 | — |
| Casdin Eli | Exercise of Derivative Securities | 18.6.2026 | 3,576 | +3,576 | — |
| Ryan Jason | Exercise of Derivative Securities | 18.6.2026 | 3,576 | +3,576 | — |
| Ryan Jason | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
| Meister Keith A. | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
| Casdin Eli | Exercise of Derivative Securities | 18.6.2026 | 3,576 | -3,576 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
6,001,270 shares short as of 2026-08-31 · vs. 5,848,506 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.3% of trading volume this week was short selling, vs. 62.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology